NuScale Power Shares Collapse 75% After $532M Quarterly Loss and Authorized Shares Doubled
NuScale Power's stock has plunged 75% from its $57 peak to $14 after reporting a $532 million quarterly net loss and failing to secure its first binding customer deal. Shareholders approved doubling authorized shares from 332 million to 662 million, heightening dilution risk and enabling additional capital raises.
1. NRC-Certified Design and First-Mover Status with No Binding Contracts
NuScale Power remains the only U.S. developer with Nuclear Regulatory Commission design certification for a small modular reactor (SMR), giving it an exclusive first-mover position. Despite that advantage, the company has yet to secure a binding customer agreement. Discussions with Romanian utility RoPower and the Tennessee Valley Authority’s ENTRA1 Energy have not progressed into signed contracts, leaving revenue visibility uncertain. Investors should watch the RoPower project closely; its ultimate success or failure will be a critical indicator of NuScale’s ability to convert regulatory approval into long-term orders.
2. Steep Stock Decline and Recent Quarterly Results Highlight Cash Runway Risks
NuScale’s stock has plunged roughly 75% from its $57 peak to about $14 today, and is down nearly 30% just in December. In its latest quarter, the company reported a net loss of $532 million and revenue of $8.24 million, missing consensus estimates of $11.29 million. Cash and equivalents stood at $754 million, although $475 million of that balance reflects proceeds from issuing 13.2 million shares. At current burn rates—quarterly cash outflows averaged $150 million over the past three quarters—investors should monitor liquidity closely, particularly given the absence of new customer deposits or milestone payments.
3. Share Dilution Concerns and Mixed Analyst Outlook
Shareholders recently approved a measure to increase authorized shares from 332 million to 662 million, creating the flexibility for further equity issuances when additional capital is needed. Analyst sentiment is broadly cautious: out of 17 firms covering SMR, five recommend sell, eight hold, and four buy, resulting in a consensus “Reduce” rating with an average 12-month target of $35.18. The divergent views reflect confidence in long-term SMR potential versus skepticism over execution risks, funding requirements and the lack of a confirmed reactor order.